| 1 |
Lissing M, Vassiliou D, Floderus Y, Harper P, Yan J, Hagström H, Sardh E, Wahlin S. Risk for incident comorbidities, nonhepatic cancer and mortality in acute hepatic porphyria: A matched cohort study in 1244 individuals. J Inherit Metab Dis 2023;46:286-99. [PMID: 36546345 DOI: 10.1002/jimd.12583] [Reference Citation Analysis]
|
| 2 |
Wang B, Bonkovsky HL, Lim JK, Balwani M. AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review. Gastroenterology 2023;164:484-91. [PMID: 36642627 DOI: 10.1053/j.gastro.2022.11.034] [Reference Citation Analysis]
|
| 3 |
Lissing M, Vassiliou D, Harper P, Sardh E, Wahlin S. Comment on Ramai et al. Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic Review. Cancers 2022, 14, 2947. Cancers (Basel) 2023;15. [PMID: 36765753 DOI: 10.3390/cancers15030795] [Reference Citation Analysis]
|
| 4 |
Jericó D, Córdoba KM, Sampedro A, Jiang L, Joucla G, Cabanne C, Lanciego JL, Martini PGV, Berraondo P, Ávila MA, Fontanellas A. Recent Insights into the Pathogenesis of Acute Porphyria Attacks and Increasing Hepatic PBGD as an Etiological Treatment. Life (Basel) 2022;12. [PMID: 36430993 DOI: 10.3390/life12111858] [Reference Citation Analysis]
|
| 5 |
Fabian E, Reisinger A, Ribitsch W, Stadlbauer V, Eherer AJ, Roller-wirnsberger R, Toplak H, Fickert P, Krejs GJ. Clinical-Pathological Conference Series from the Medical University of Graz. Wien Klin Wochenschr 2022. [DOI: 10.1007/s00508-022-02097-w] [Reference Citation Analysis]
|
| 6 |
To-Figueras J, Titos E, Aguilera P, Díaz A, Muñoz-Luque J, Madrigal I, Badenas C, Torra M, Fondevila C, Colmenero J. Transcriptomic study in explanted liver from a patient with acute intermittent porphyria. JIMD Rep 2023;64:10-6. [PMID: 36636600 DOI: 10.1002/jmd2.12329] [Reference Citation Analysis]
|
| 7 |
Wang B, Ventura P, Takase KI, Thapar M, Cassiman D, Kubisch I, Liu S, Sweetser MT, Balwani M. Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study. Orphanet J Rare Dis 2022;17:327. [PMID: 36028858 DOI: 10.1186/s13023-022-02463-x] [Reference Citation Analysis]
|
| 8 |
Ghasemzad M, Hashemi M, Lavasani ZM, Hossein-khannazer N, Bakhshandeh H, Gramignoli R, Keshavarz Alikhani H, Najimi M, Nikeghbalian S, Vosough M. Novel Gene-Correction-Based Therapeutic Modalities for Monogenic Liver Disorders. Bioengineering 2022;9:392. [DOI: 10.3390/bioengineering9080392] [Reference Citation Analysis]
|
| 9 |
Kasahara M, Sakamoto S, Fukuda A, Uchida H, Yi NJ, Schlegel A, Muiesan P, Qiang X, Gao W, Zhu ZJ, Rodriguez-Davalos M, Rela M. Marginal parental donors for pediatric living donor liver transplantation. Curr Opin Organ Transplant 2022;27:346-50. [PMID: 36354261 DOI: 10.1097/MOT.0000000000000990] [Reference Citation Analysis]
|
| 10 |
Majeed CN, Ma CD, Xiao T, Rudnick S, Bonkovsky HL. Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy. DDDT 2022;Volume 16:1827-1845. [DOI: 10.2147/dddt.s281631] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
Schulenburg-Brand D, Stewart F, Stein P, Rees D, Badminton M. Update on the diagnosis and management of the autosomal dominant acute hepatic porphyrias. J Clin Pathol 2022:jclinpath-2021-207647. [PMID: 35584894 DOI: 10.1136/jclinpath-2021-207647] [Reference Citation Analysis]
|
| 12 |
Ventura P, Ricci A. Givosiran for the treatment of acute hepatic porphyria. Expert Review of Clinical Pharmacology. [DOI: 10.1080/17512433.2022.2075848] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 13 |
Sardh E, Harper P. RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria. J Intern Med 2022;291:593-610. [PMID: 35067977 DOI: 10.1111/joim.13443] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 14 |
Longo M, Paolini E, Meroni M, Dongiovanni P. Cutting-Edge Therapies and Novel Strategies for Acute Intermittent Porphyria: Step-by-Step towards the Solution. Biomedicines 2022;10:648. [DOI: 10.3390/biomedicines10030648] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 15 |
Baumann K, Kauppinen R. Long-term follow-up of acute porphyria in female patients: Update of clinical outcome and life expectancy. Molecular Genetics and Metabolism Reports 2022;30:100842. [DOI: 10.1016/j.ymgmr.2022.100842] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 16 |
Córdoba KM, Serrano-Mendioroz I, Jericó D, Merino M, Jiang L, Sampedro A, Alegre M, Corrales F, Garrido MJ, Martini PGV, Lanciego JL, Prieto J, Berraondo P, Fontanellas A. Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria. Sci Transl Med 2022;14:eabc0700. [PMID: 35020410 DOI: 10.1126/scitranslmed.abc0700] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 17 |
Lourenço CM, Anderson KE. Disorders of Haem Biosynthesis. Inborn Metabolic Diseases 2022. [DOI: 10.1007/978-3-662-63123-2_33] [Reference Citation Analysis]
|
| 18 |
Ricci A, Guida CC, Manzini P, Cuoghi C, Ventura P. Kidney Involvement in Acute Hepatic Porphyrias: Pathophysiology and Diagnostic Implications. Diagnostics (Basel) 2021;11:2324. [PMID: 34943561 DOI: 10.3390/diagnostics11122324] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 19 |
Ricci A, Di Pierro E, Marcacci M, Ventura P. Mechanisms of Neuronal Damage in Acute Hepatic Porphyrias. Diagnostics (Basel) 2021;11:2205. [PMID: 34943446 DOI: 10.3390/diagnostics11122205] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 20 |
de Souza PVS, Badia BML, Farias IB, Pinto WBVR, Oliveira ASB. Acute Hepatic Porphyria: Pathophysiological Basis of Neuromuscular Manifestations. Front Neurosci 2021;15:715523. [PMID: 34646118 DOI: 10.3389/fnins.2021.715523] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 21 |
da Fonseca Neto OCL, Moutinho LER, Filgueira NA, Jucá NT, Rabêlo PJM, de Melo PSV, Amorim AG, Lacerda CM. Recurrence of mild neuropathic pain, following deceased donor liver transplantation, in patient with acute intermittent porphyria: Could timing explain it? A case report. Journal of Liver Transplantation 2021;4:100039. [DOI: 10.1016/j.liver.2021.100039] [Reference Citation Analysis]
|
| 22 |
Erwin AL, Balwani M. Porphyrias in the Age of Targeted Therapies. Diagnostics (Basel) 2021;11:1795. [PMID: 34679493 DOI: 10.3390/diagnostics11101795] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 23 |
Menon J, Vij M, Sachan D, Rammohan A, Shanmugam N, Kaliamoorthy I, Rela M. Pediatric metabolic liver diseases: Evolving role of liver transplantation. World J Transplant 2021; 11(6): 161-179 [PMID: 34164292 DOI: 10.5500/wjt.v11.i6.161] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 24 |
Moghe A, Anderson KE. Expanding Experience With Liver Transplantation in Acute Intermittent Porphyria. Liver Transpl 2021;27:477-8. [PMID: 33369869 DOI: 10.1002/lt.25979] [Reference Citation Analysis]
|
| 25 |
Moghe A, Anderson KE. Porphyrias: Acute Manifestations. Contemporary Endocrinology 2021. [DOI: 10.1007/978-3-030-67455-7_20] [Reference Citation Analysis]
|
